Details for 2020211096

Up to date per 02.04.2026

Actions

Title / Product Name

(R) UND (S) ENANTIOMERE DES N-(5-(3-HYDROXYPYRROLIDIN-1-YL)-2-MORPHOLINOOXAZOLO[4,5-B]PYRIDIN-6-YL)-2-(2-METHYLPYRIDIN-4-YL)OXAZOL-CARBOXAMIDS ALS IRAK4-INHIBITOREN ZUR BEHANDLUNG VON KREBS

Status

Granted/Registered

Protection Type

European Patent

(AT-) Application Number

2020211096

EP Publication Number

3805233

E-Number

1663420

Language

PCT Number

Publication Date

14.04.2021 A

06.03.2024 B1

Registration Date

06.03.2024

AT Publication Date

15.03.2024

Application Date

12.01.2015

Registration Number

Priorities

13.01.2014

158CH2014

20.06.2014

3000CH2014

IPC

C07D 498/04 20060101AFI20210205BHEP

Maximum Duration of Protection

12.01.2035

Owner

Aurigene Oncology Limited39-40 KIADB Industrial Area Electronic City Phase II Hosur Road Bangalore 560100IN

Representative

No representatives present

Inventor

GUMMADI, Venkateshwar, RaoBalaji Nilayam 62 1st main Veerabhadraswamylayout Doddanagamangala Electronic City 560100 BangaloreIN

SAMAJDAR, SusantaFlat R801 H. M Tambourine Jaraganahalli J.P. Nagar 6th Phase 560078 BangaloreIN

Information about Fees